SCHEMBL8264263

SCHEMBL8264263

CC(C)(C)OC(=O)N1CCC(c2cccc(-c3ccccc3)c2)=C(C(=O)NCC(F)F)C1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 7/20 0.46
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
ACKR3 P25106 1/20 0.41
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
KAT7 O95251 1/20 0.40
KAT8 Q9H7Z6 1/20 0.40
MGAT2 Q10469 1/20 0.39
DGAT2 Q96PD7 1/20 0.39
ESR2 Q92731 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
NR1H2 P55055 1/20 0.39
BACE1 P56817 1/20 0.38
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8263342 0.89 USP30 (0.46) USP30CTSSCTSKACKR3KDM4E
SCHEMBL8264258 0.89 USP30 (0.46) USP30CTSSCTSKACKR3KDM4E
SCHEMBL8263837 0.89 USP30 (0.44) USP30CTSSCTSKACKR3KDM4E
SCHEMBL8265036 0.86 USP30 (0.48) USP30CTSSCTSKACKR3ESR2
SCHEMBL8264170 0.86 USP30 (0.48) USP30KDM4EPKMESR2HDAC1
SCHEMBL8264160 0.84 USP30 (0.47) USP30ESR2GPR119NR1H2
SCHEMBL8261717 0.83 CHRM2 (0.51) USP30MGAT2DGAT2ESR2NR1H2
SCHEMBL8263337 0.83 ACHE (0.46) USP30CTSSCTSKACKR3MGAT2
SCHEMBL8264161 0.83 USP30 (0.56) USP30ACKR3KDM4EPKMESR2
SCHEMBL2242238 0.81 CHRM5 (0.53) USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029647-A1 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES NOVARTIS AG (CH) 2010-02-04 US disclosed
US-20100029647-A1 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES NOVARTIS AG (CH) 2010-02-04 US disclosed
WO-2006074924-A1 3,4,(5)-SUBSTITUTED TETRAHVDROPYRIDINES NOVARTIS AG (CH) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029647-A1 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES REN, PAH, ACE USP30 4527/4885CTSS 1284/4885CTSK 2223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.